
Rapid insulin discontinuation occurred with tirzepatide 2.5 mg weekly in long-standing type 2 diabetes, demonstrating a low-dose responder phenotype and pharmacist-led CGM-guided deprescribing.

Rapid insulin discontinuation occurred with tirzepatide 2.5 mg weekly in long-standing type 2 diabetes, demonstrating a low-dose responder phenotype and pharmacist-led CGM-guided deprescribing.